Moderna and merck announce mrna-4157 (v940) in combination with keytruda(r) (pembrolizumab) demonstrated continued improvement in recurrence-free survival and distant metastasis-free survival in patients with high-risk stage iii/iv melanoma following complete resection versus keytruda at three years

At a median planned follow-up of approximately three years, mrna-4157 (v940) in combination with keytruda reduced the risk of recurrence or death by 49% (hr=0.510 [95% ci, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (hr=0.384 [95% ci, 0.172-0.858]; one-sided nominal p= 0.0077) compared to keytruda alone in stage iii/iv melanoma patients with high risk of recurrence following complete resection data builds on the primary analysis reported at aacr and asco in 2023, which showed that mrna-4157 (v940) in combination with keytruda reduced the risk of recurrence or death by 44% and reduced the risk of distant metastasis or death by 65% at a median planned follow-up of approximately two years companies have initiated phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types cambridge, ma and rahway, nj / accesswire / december 14, 2023/ moderna, inc. (nasdaq:mrna) and merck (nyse:mrk), known as msd outside of the united states and canada, today announced follow-up data from the phase 2b randomized keynote-942/mrna-4157-p201 study, a clinical trial evaluating mrna-4157 (v940), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, in patients with resected high-risk melanoma (stage iii/iv) following complete resection. in this planned analysis occurring with a median follow-up of approximately three years, adjuvant treatment with mrna-4157 (v940) in combination with keytruda continued to demonstrate a clinically meaningful improvement in recurrence-free survival (rfs), reducing the risk of recurrence or death by 49% (hr=0.510 [95% ci, 0.288-0.906]; one-sided nominal p=0.0095) compared with keytruda alone.
MRNA Ratings Summary
MRNA Quant Ranking